The 2-week treatment with sunitinib reduced tyrosine phosphorylation of VEGFR2 and PDGFRβ in both the serous carcinoma (LTL247) and CCOC (LTL175) tissues to very low levels. Here, PDGFRB is linked to serous adenocarcinoma.